Showing results (261-270 of 831) with videos related to

Sort By:
Pageof 84
Cancer|October 21, 2010
Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinibFabio P S Santos, Yesid Alvarado, Hagop Kantarjian, et al.
European Journal of Haematology|September 3, 2003
Molecular differences between small and large cells in patients with chronic lymphocytic leukemiaJeong N Lee, Fancis Giles, Yang O Huh, et al.
Blood|March 15, 2015
Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trialJennifer R Brown, Susan O'Brien, C Daniel Kingsley, et al.
Cancer|March 13, 2009
Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapyAlfonso Quintás-Cardama, Hagop Kantarjian, Farhad Ravandi, et al.
Cancer|October 11, 2008
Outcome of adults with acute lymphocytic leukemia after second salvage therapySusan O'Brien, Deborah Thomas, Farhad Ravandi, et al.
British Journal of Haematology|July 14, 2011
Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistanceMarek Mraz, Clive S Zent, Amy K Church, et al.
British Journal of Haematology|November 18, 2003
Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemiaDeborah A Thomas, Elihu Estey, Francis J Giles, et al.
Cancer|January 26, 2006
Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndromeHagop Kantarjian, Miloslav Beran, Jorge Cortes, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 25, 2012
Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabineElias Jabbour, Guillermo Garcia-Manero, Farhad Ravandi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2013
A phase 1, dose-escalation, pharmacokinetic and pharmacodynamic study of BIIB021 administered orally in patients with advanced solid tumorsMuhammad Wasif Saif, Chris Takimoto, Monica Mita, et al.
Pageof 84